The U.S. Food and Drug Administration (FDA) has granted full approval to exa-cel (exagamglogene autotemcel) the first CRISPR-Cas9 gene-editing therapy for sickle cell disease (SCD) . This landmark approval follows pivotal Phase III results showing that over 90% of treated patients remained free of vaso-occlusive crises for more than 12 months post-therapy. The treatment works by editing the patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, effectively preventing sickling of red blood cells.
While the therapy represents a potential functional cure , high manufacturing costs and complex logistics currently limit accessibility to specialized centers. Experts view this as a major step toward precision medicine in hematology , paving the way for gene-editing applications in thalassemia and other inherited disorders. Do you believe gene-editing therapies like…
